Dimension Therapeutics Inc. (DMTX) Sees Large Volume Increase

dimension-therapeutics-inc-dmtx-sees-large-volume-increase.png

Shares of Dimension Therapeutics Inc. (NASDAQ:DMTX) saw strong trading volume on Tuesday . 82,900 shares traded hands during mid-day trading, an increase of 52% from the previous session’s volume of 54,593 shares.The stock last traded at $8.94 and had previously closed at $8.95.
Several research analysts recently commented on the stock. Zacks Investment Research raised shares of Dimension Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, August 24th. Cantor Fitzgerald reissued a “buy” rating on shares of Dimension Therapeutics in a report on Wednesday, June 22nd. Chardan Capital set a $10.00 price target on shares of Dimension Therapeutics and gave the company a “hold” rating in a report on Sunday, August 21st. Canaccord Genuity set a $20.00 price target on shares of Dimension Therapeutics and gave the company a “buy” rating in a report on Thursday, August 11th. Finally, Jefferies Group initiated coverage on shares of Dimension Therapeutics in a report on Thursday, June 2nd. They issued a “buy” rating and a $12.00 price target for the company. Three analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $17.19.
The company’s market capitalization is $226.26 million. The stock has a 50 day moving average price of $6.82 and a 200-day moving average price of $7.36.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/13/dimension-therapeutics-inc-dmtx-sees-large-volume-increase.html

Dimension Therapeutics (NASDAQ:DMTX) last posted its earnings results on Thursday, August 11th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.43) by $0.06. Dimension Therapeutics had a negative net margin of 459.47% and a negative return on equity of 66.58%. On average, analysts predict that Dimension Therapeutics Inc. will post ($1.91) earnings per share for the current fiscal year.
Several institutional investors have recently bought and sold shares of the stock. BlackRock Institutional Trust Company N.A. raised its position in Dimension Therapeutics by 0.3% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 29,152 shares of the company’s stock valued at $228,000 after buying an additional 89 shares during the period. Teachers Advisors Inc. raised its position in Dimension Therapeutics by 224.3% in the second quarter. Teachers Advisors Inc. now owns 19,204 shares of the company’s stock valued at $115,000 after buying an additional 13,283 shares during the period. California State Teachers Retirement System raised its position in Dimension Therapeutics by 113.2% in the second quarter. California State Teachers Retirement System now owns 25,634 shares of the company’s stock valued at $154,000 after buying an additional 13,610 shares during the period. Bank of New York Mellon Corp raised its position in Dimension Therapeutics by 180.8% in the second quarter. Bank of New York Mellon Corp now owns 28,743 shares of the company’s stock valued at $173,000 after buying an additional 18,506 shares during the period. Finally, Highbridge Capital Management LLC purchased a new position in Dimension Therapeutics during the second quarter valued at $123,000. 85.80% of the stock is owned by hedge funds and other institutional investors.
Dimension Therapeutics Company Profile
Dimension Therapeutics, Inc is a gene therapy company. The Company is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. It has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa).

Receive News & Ratings for Dimension Therapeutics Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Dimension Therapeutics Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.

Be the first to comment on "Dimension Therapeutics Inc. (DMTX) Sees Large Volume Increase"

Leave a comment

Your email address will not be published.


*